Landsberg Bennett & Dubbaneh’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
$239K Sell
5,564
-1,086
-16% -$48.1K 0.03% 251
2021
Q2
$260K Sell
6,650
-670
-9% -$26.1K 0.03% 245
2021
Q1
$266K Sell
7,320
-3,404
-32% -$121K 0.04% 232
2020
Q4
$395K Sell
10,724
-12,973
-55% -$476K 0.06% 173
2020
Q3
$813K Sell
23,697
-37
-0.2% -$1.3K 0.14% 121
2020
Q2
$735K Buy
23,734
+493
+2% +$16.7K 0.15% 119
2020
Q1
$725K Sell
23,241
-39,605
-63% -$1.35M 0.2% 91
2019
Q4
$2.32M Sell
62,846
-30,682
-33% -$1.09M 0.54% 72
2019
Q3
$3.21M Buy
93,528
+2,086
+2% +$75.9K 0.86% 41
2019
Q2
$3.8M Buy
91,442
+5,774
+7% +$229K 0.99% 31
2019
Q1
$3.48M Buy
85,668
+27,012
+46% +$1.08M 0.82% 37
2018
Q4
$2.43M Buy
+58,656
New +$2.43M 0.93% 25

Other funds holding PFE

Landsberg Bennett & Dubbaneh's PFE Position: Q3 2021 in Review

Landsberg Bennett & Dubbaneh reduced its Pfizer (PFE) stake by 16% in Q3 2021, selling an estimated $48.1K and leaving 5,564 shares worth $239K. The position accounts for 0.03% of the portfolio, ranked #251.

Landsberg Bennett & Dubbaneh first reported a position in PFE in Q4 2018 and has held it in 12 quarters since. The position peaked at $3.8M in Q2 2019. 2,804 funds tracked by Wall St. Rank hold PFE as of Q3 2021.

  • Landsberg Bennett & Dubbaneh held 5,564 shares of Pfizer worth $239K as of Q3 2021.
  • Landsberg Bennett & Dubbaneh sold 1,086 Pfizer shares in Q3 2021, an estimated $48.1K.
  • Pfizer made up 0.03% of Landsberg Bennett & Dubbaneh's portfolio in Q3 2021, its #251 holding.
  • Landsberg Bennett & Dubbaneh first reported a position in Pfizer in Q4 2018 and has held it in 12 quarters since.
  • Landsberg Bennett & Dubbaneh's Pfizer position peaked at $3.8M in Q2 2019.
  • 2,804 funds tracked by Wall St. Rank held Pfizer as of Q3 2021.

Based on Landsberg Bennett & Dubbaneh's 13F filing for Q3 2021, filed 29 Oct 2021.